Abstract
We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection. One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia. We recommend caution in the use of lopinavir/ritonavir in the immediate neonatal period.
MeSH terms
-
Diseases in Twins / chemically induced
-
Electrocardiography
-
Female
-
HIV Protease Inhibitors / adverse effects*
-
HIV Protease Inhibitors / therapeutic use
-
Heart / drug effects*
-
Heart Block
-
Heart Diseases / chemically induced*
-
Humans
-
Infant, Newborn
-
Infant, Premature*
-
Infectious Disease Transmission, Vertical / prevention & control
-
Lopinavir
-
Pyrimidinones / adverse effects*
-
Pyrimidinones / therapeutic use
-
Ritonavir / adverse effects*
-
Ritonavir / therapeutic use
-
Twins*
Substances
-
HIV Protease Inhibitors
-
Pyrimidinones
-
Lopinavir
-
Ritonavir